According to a recent report by Pablo Zuanic of Zuanic & Associates, MariMed (OTC: MRMD) a multi-state cannabis operator (MSO) is positioned for significant stock gains.
Analyst projects significant growth for XPeng's G6 EV, driving a 63% CAGR in vehicle sales and market share increase to 4%, with strong software revenue contribution.
Target reported a first-quarter FY24 sales decline of 3.1% year-on-year to $24.531 billion, with comparable sales down 3.7%. Adjusted EPS was $2.03, missing the consensus estimate of $2.06. BofA Securities reiterated a Buy rating with a $190 price target. Telsey Advisory Group reiterated an Outperform rating with a $195 price target, highlighting outperformance in beauty and future market share gains.